Literature DB >> 33621251

Quality of life and its associated factors among epileptic patients attending public hospitals in North Wollo Zone, Northeast Ethiopia: A cross-sectional study.

Ayelign Mengesha Kassie1, Biruk Beletew Abate1, Mesfin Wudu Kassaw1, Addisu Getie1, Adam Wondmieneh1, Kindie Mekuria Tegegne1, Mohammed Ahmed2.   

Abstract

BACKGROUND: Epilepsy is thought to be caused by witchcraft, evil spirit, and God's punishment for sins in many developing countries. As a result, people with epilepsy and their families usually suffer from stigma, discrimination, depression, and other psychiatric problems. Thus, this study aimed to assess the quality of life and its associated factors among epileptic patients attending public hospitals in North Wollo Zone, Northeast Ethiopia.
METHODS: An institution-based cross-sectional study design was employed in this study. A simple random sampling technique was utilized. Health-related quality of life was measured based on the total score of the Quality of Life in Epilepsy Inventory (QOLIE-31) instrument. Data were entered into Epi-data 3.1 statistical package and exported to SPSS Version 20 for further analysis. Linear regression models were used to assess the relationship between quality of life and the independent variables. Statistically significant values were declared at a P-value of < 0.05.
RESULTS: A total of 395 patients participated in the study making the response rate 98.5%. The mean age of the participants was 32.39 ±10.71 years. More than half, 199 (50.4%) of epileptic patients had an overall weighted average health related quality of life score of mean and above. Male sex (B = 4.34, 95%CI, 0.41, 8.27, P = 0.03), higher educational status (B = 7.18, 95%CI, 1.39, 13.00, P = 0.015) and age at onset of epilepsy (B = 0.237, 95%CI, 0.02, 0.45, P = 0.035) were associated with increased health related quality of life score. On the other hand, family history of epilepsy (B = -4.78, 95%CI,-9.24,-0.33, P = 0.035), uncontrolled seizure (B = -11.08, 95%CI,-15.11,-7.05, P < 0.001), more than 5 pre-treatment number of seizures (B = -4.86, 95%CI,-8.91,-0.81, P = 0.019), poor drug adherence (B = -11.65, 95%CI,-16.06,-7.23, P < 0.001), having moderate (B = -4.526, 95%CI,-8.59,-0.46, P = 0.029) to sever (B = -12.84, 95%CI,-18.30,-7.37, P < 0.001) anxiety and depression, believing that epilepsy is caused by evil spirit (B = -7.04, 95%CI,-11.46,-2.61, P = 0.002), drinking alcohol (B = -5.42, 95%CI,-10.72,-0.13, P = 0.045), and having other co-morbidities (B = -9.35, 95%CI,-14.35,-4.36, P < 0.001) were significantly negatively associated with the health related quality of life score among epileptic patients.
CONCLUSIONS: Only around half of the epileptic patients have a good health-related quality of life. In addition, multiple variables including family history, uncontrolled seizure, and poor drug adherence were associated with quality of life among epileptic patients. Hence, targeting these variables in epilepsy management is recommended.

Entities:  

Year:  2021        PMID: 33621251      PMCID: PMC7901738          DOI: 10.1371/journal.pone.0247336

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  41 in total

1.  Myths, misconceptions, and misunderstandings about epilepsy in a Nigerian rural community: implications for community health interventions.

Authors:  Kayode O Osungbade; Sunday L Siyanbade
Journal:  Epilepsy Behav       Date:  2011-06-25       Impact factor: 2.937

2.  An ultra-brief screening scale for anxiety and depression: the PHQ-4.

Authors:  Kurt Kroenke; Robert L Spitzer; Janet B W Williams; Bernd Löwe
Journal:  Psychosomatics       Date:  2009 Nov-Dec       Impact factor: 2.386

3.  Potential factors impacting health-related quality of life among patients with epilepsy: Results from the United Arab Emirates.

Authors:  Taoufik Alsaadi; Seada Kassie; Khadija El Hammasi; Tarek M Shahrour; Mustafa Shakra; Lamya Turkawi; Wassim Nasreddine; Mufeed Raoof
Journal:  Seizure       Date:  2017-10-28       Impact factor: 3.184

Review 4.  Early predictors of outcome in newly diagnosed epilepsy.

Authors:  Rajiv Mohanraj; Martin J Brodie
Journal:  Seizure       Date:  2013-04-11       Impact factor: 3.184

Review 5.  Epilepsy and employment: literature review.

Authors:  Vivian M J Smeets; Brigitte A G van Lierop; Jos P G Vanhoutvin; Albert P Aldenkamp; Frans J N Nijhuis
Journal:  Epilepsy Behav       Date:  2007-03-21       Impact factor: 2.937

6.  Quality of life in epilepsy in Bhutan.

Authors:  Altaf Saadi; Bryan Patenaude; Damber Kumar Nirola; Sonam Deki; Lhab Tshering; Sarah Clark; Lance Shaull; Tali Sorets; Guenther Fink; Farrah Mateen
Journal:  Seizure       Date:  2016-05-10       Impact factor: 3.184

7.  Epilepsy in Laos: knowledge, attitudes, and practices in the community.

Authors:  Duc-Si Tran; Peter Odermatt; Soukhanthone Singphuoangphet; Michel Druet-Cabanac; Pierre-Marie Preux; Michel Strobel; Hubert Barennes
Journal:  Epilepsy Behav       Date:  2007-04-18       Impact factor: 2.937

8.  The quality of life and inequalities in health services for epilepsy treatment among patience in the urban cities of Sudan.

Authors:  Muwada Bashir Awad Bashir; Samuel Nambile Cumber
Journal:  Pan Afr Med J       Date:  2019-05-07

9.  Community's Perception and Attitude towards People with Epilepsy in Ethiopia.

Authors:  Wubalem Fekadu; Tesfa Mekonen; Shemelash Bitew; Tefera Chanie Mekonnen; Melak Menberu; Seble Shewangizaw
Journal:  Behav Neurol       Date:  2019-11-07       Impact factor: 3.342

10.  Assessment of Quality of Life of Epileptic Patients in Ethiopia.

Authors:  Esileman Abdela Muche; Mohammed Biset Ayalew; Ousman Abubeker Abdela
Journal:  Int J Chronic Dis       Date:  2020-01-02
View more
  1 in total

1.  Level of Acceptance of Illness and Its Association with Quality of Life among Patients with Epilepsy in North Shewa, Ethiopia.

Authors:  Yonas Teshome; Yerukneh Solomon; Feredegn Talargia; Negese Worku; Abreham Shitaw; Abebaye Aragaw Leminie
Journal:  Behav Neurol       Date:  2022-09-12       Impact factor: 3.112

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.